Payment overview · 2025
General Payments
$284.21
15 reported records · 9 companies
Healthcare provider profile · identity verified
Ryan Ashley Forbess, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ORANGE BEACH, AL · NPI 1508155805
Verified facts
What the public records show
CMS Open Payments records show Ryan Ashley Forbess, M.D. received $284.21 in general payments during 2025 across 15 reported records.
Lilly USA, LLC accounted for 20.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta, Xyosted.
Antares Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYOSTED as an associated drug or biological on 18015 records involving 7619 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Xyosted by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 443 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $59.50 | 20.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.23 | 17.3% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $39.11 | 13.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.53 | 11.8% | 2 | 2025 |
| AGEPHA Pharma FZ LLC | Unresolved — no canonical attribution shown | $32.79 | 11.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.16 | 8.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.88 | 5.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.13 | 5.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.88 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $239.21 | 14 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $39.11 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.77 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.53 | 2 | 2025 |
Source payment records
|
|||||
| LODOCO Normalized: lodoco |
Drug | AGEPHA Pharma FZ LLC | $32.79 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $14.50 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 61 | exact normalized | Medicare Part D |
| XYOSTED xyosted |
2025 | Xyosted | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Antares Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | XYOSTED open payments reported associated product |
CMS Open Payments — General Payments 18015 supporting records · 7619 recipient NPIs · example record 1235880452 |
Xyosted · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
443 | 77 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
120 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 502 | 174 |
| Levothyroxine Sodium | Levothyroxine Sodium | 488 | 154 |
| Amlodipine Besylate | Amlodipine Besylate | 453 | 166 |
| Mounjaro | Tirzepatide | 443 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 408 | 146 |
| Losartan Potassium | Losartan Potassium | 367 | 128 |
| Ozempic | Semaglutide | 349 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 324 | 124 |
| Metformin Hcl Er | Metformin Hcl | 290 | 101 |
| Metoprolol Succinate | Metoprolol Succinate | 248 | 92 |
| Lisinopril | Lisinopril | 239 | 76 |
| Gabapentin | Gabapentin | 224 | 73 |
| Montelukast Sodium | Montelukast Sodium | 198 | 79 |
| Meloxicam | Meloxicam | 189 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 66 |
| Cefdinir | Cefdinir | 163 | 125 |
| Omeprazole | Omeprazole | 161 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 154 | 53 |
| Fluticasone Propionate | Fluticasone Propionate | 152 | 61 |
| Trazodone Hcl | Trazodone Hcl | 152 | 47 |
| Temazepam | Temazepam | 150 | 37 |
| Simvastatin | Simvastatin | 147 | 44 |
| Furosemide | Furosemide | 136 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 125 | 40 |
| Metformin Hcl | Metformin Hcl | 123 | 46 |
| Eliquis | Apixaban | 120 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 42 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 116 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 106 | 45 |
| Allopurinol | Allopurinol | 99 | 37 |
| Ezetimibe | Ezetimibe | 96 | 40 |
| Tramadol Hcl | Tramadol Hcl | 89 | 24 |
| Sertraline Hcl | Sertraline Hcl | 87 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 86 | 31 |
| Potassium Chloride | Potassium Chloride | 84 | 31 |
| Carvedilol | Carvedilol | 81 | 27 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 80 | 57 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 40 |
| Ondansetron Odt | Ondansetron | 73 | 34 |
| Clonazepam | Clonazepam | 71 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 22 |
| Bupropion Xl | Bupropion Hcl | 67 | 26 |
| Celecoxib | Celecoxib | 67 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 63 | 26 |
| Trulicity | Dulaglutide | 63 | 15 |
| Methylprednisolone | Methylprednisolone | 62 | 52 |
| Jardiance | Empagliflozin | 61 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 17 |
| Fluconazole | Fluconazole | 60 | 39 |
| Buspirone Hcl | Buspirone Hcl | 59 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 18 |
| Folic Acid | Folic Acid | 57 | 25 |
| Testosterone Cypionate | Testosterone Cypionate | 57 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 52 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 52 | 42 |
| Alprazolam | Alprazolam | 51 | 17 |
| Liothyronine Sodium | Liothyronine Sodium | 50 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 11 |
| Famotidine | Famotidine | 47 | 14 |
| Pregabalin | Pregabalin | 47 | 11 |
| Mupirocin | Mupirocin | 46 | 34 |
| Ofloxacin | Ofloxacin | 44 | 38 |
| Diclofenac Sodium Er | Diclofenac Sodium | 42 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 40 | 19 |
| Tresiba Flextouch U-200 | Insulin Degludec | 38 | 12 |
| Ibuprofen | Ibuprofen | 37 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Anastrozole | Anastrozole | 32 | 11 |
| Estradiol | Estradiol | 31 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | 11 |
| Atenolol | Atenolol | 29 | 11 |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | 12 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 23 |
| Valsartan | Valsartan | 26 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 19 |
| Fenofibrate | Fenofibrate | 25 | 11 |
| Lovastatin | Lovastatin | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 18 |
| Colchicine | Colchicine | 22 | 12 |
| Meclizine Hcl | Meclizine Hcl | 22 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | 11 |
| Prednisone | Prednisone | 21 | 15 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 15 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | 12 |
| Wegovy | Semaglutide | 15 | suppressed |
| Xyosted | Testosterone Enanthate | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $284.21 · 15 records | Lilly USA, LLC | AIRSUPRA, AMYVID, FARXIGA, KISUNLA, LODOCO, OTEZLA, RELISTOR, REPATHA, TRELEGY ELLIPTA, VOQUEZNA, VYNDAMAX, XYOSTED | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Antares Pharma, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error